Differential effects of endocannabinoids on[3H]-GABA uptake in the rat globus pallidus

被引:22
作者
Venderova, K
Brown, TM
Brotchie, JM
机构
[1] Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada
[2] Univ Manchester, Sch Biol Sci, Manchester, Lancs, England
关键词
endocannabinoid; Parkinson's disease; globus pallidus; basal ganglia; cannabinoid; CB1; anandamide; 2-AG; noladin ether; GABA;
D O I
10.1016/j.expneurol.2005.02.012
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In the globus pallidus, cannabinoid CB1 receptors are localized pre-synaptically on GABAergic neurons, We assessed the influence of the endocannabinoids, anandamide, 2-arachidonoyl-glycerol (2-AG) and noladin ether. on the uptake of [H-3]-GABA in pallidal slices from rat. Both 2-AG and noladin ether increased [H-3]-GABA uptake (by 40.8 +/- 8.0% and 38 +/- 12.5%). The effect ct of 2-AG was blocked by the cannabinoid CB1 receptor antagonist AM 251. In contrast, neither anandamide nor the agonist WIN 55.212-2 had in eflect on [H-3]-GABA uptake. Different roles might be played by different endocannabinoids, both physiologically and in basal ganglia disorders. such as Parkinson's disease. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:284 / 287
页数:4
相关论文
共 25 条
  • [1] Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
    Bezard, E
    Gross, CE
    Brotchie, JM
    [J]. TRENDS IN NEUROSCIENCES, 2003, 26 (04) : 215 - 221
  • [2] Evidence for a new G protein-coupled cannabinoid receptor in mouse brain
    Breivogel, CS
    Griffin, G
    Di Marzo, V
    Martin, BR
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (01) : 155 - 163
  • [3] CB1 cannabinoid receptor signalling in Parkinson's disease
    Brotchie, JM
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (01) : 54 - 61
  • [4] Behavioral effects of cannabinoid agents in animals
    Chaperon, F
    Thiébot, MH
    [J]. CRITICAL REVIEWS IN NEUROBIOLOGY, 1999, 13 (03): : 243 - 281
  • [5] Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
    Di Marzo, V
    Hill, MP
    Bisogno, T
    Crossman, AR
    Brotchie, JM
    [J]. FASEB JOURNAL, 2000, 14 (10) : 1432 - 1438
  • [6] Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
    Di Marzo, V
    Melck, D
    Bisogno, T
    De Petrocellis, L
    [J]. TRENDS IN NEUROSCIENCES, 1998, 21 (12) : 521 - 528
  • [7] Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis -: a difficult issue to handle
    Fowler, CJ
    Tiger, G
    Ligresti, A
    López-Rodriguez, ML
    Di Marzo, V
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 492 (01) : 1 - 11
  • [8] FRIDE F, 2002, PORSTAGLANDINS LEUKO, V66, P221
  • [9] Gubellini P, 2002, J NEUROSCI, V22, P6900
  • [10] Horton N, 2001, MOL MEMBR BIOL, V18, P39